Enhancing efficacy of gemcitabine in pancreatic patient-derived xenograft mouse models
Gemcitabine (Gem), a nucleoside analog, is a preferred choice of treatment for pancreatic cancer (PCa) and often used in combination therapy against wide range of solid tumors. It is known to be rapidly inactivated in blood by cytidine deaminase. The objective of the study was to improve the systemi...
Saved in:
Main Authors: | Andriana Inkoom (Author), Nkafu Ndemazie (Author), Kevin Affram (Author), Taylor Smith (Author), Xue Zhu (Author), Patrick Underwood (Author), Sunil Krishnan (Author), Edward Ofori (Author), Bo Han (Author), Jose Trevino (Author), Edward Agyare (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2020-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Tissue distribution of crizotinib and gemcitabine combination in a patient-derived orthotopic mouse model of pancreatic cancer
by: Richard J. Honeywell, et al.
Published: (2016) -
Gemcitabine Combination Nano Therapies for Pancreatic Cancer
by: Kamalika Samanta, et al.
Published: (2019) -
Lurbinectedin induces depletion of tumor-associated macrophages, an essential component of its in vivo synergism with gemcitabine, in pancreatic adenocarcinoma mouse models
by: María Virtudes Céspedes, et al.
Published: (2016) -
Proteomic Analysis of Combined Gemcitabine and Birinapant in Pancreatic Cancer Cells
by: Xu Zhu, et al.
Published: (2018) -
Ultrasound- and Microbubble-Assisted Gemcitabine Delivery to Pancreatic Cancer Cells
by: Tormod Bjånes, et al.
Published: (2020)